

# The fragile X proteins' enigma: to be or not to be nucleolar

Edouard W Khandjian, Tom Moss, Timothy M Rose, Claude Robert, Laetitia Davidovic

### ▶ To cite this version:

Edouard W Khandjian, Tom Moss, Timothy M Rose, Claude Robert, Laetitia Davidovic. The fragile X proteins' enigma: to be or not to be nucleolar. Frontiers in Cell and Developmental Biology, 2024, 12, 10.3389/fcell.2024.1448209. hal-04728460

## HAL Id: hal-04728460 https://hal.science/hal-04728460v1

Submitted on 9 Oct 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.





#### **OPEN ACCESS**

EDITED BY

Efthimios M. C. Skoulakis. Alexander Fleming Biomedical Sciences Research Center, Greece

REVIEWED BY

Christos G. Gkogkas, Biomedical Research Institute (BRI), Greece Alexandros K. Kanellopoulos, Dsm-firmenich, Switzerland Hervé Moine. INSERM U964 Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC),

Edouard W. Khandjian, ■ edward.khandjian@crulrg.ulaval.ca

RECEIVED 13 June 2024 ACCEPTED 15 July 2024 PUBLISHED 02 August 2024

Khandjian EW, Moss T, Rose TM, Robert C and Davidovic L (2024). The fragile X proteins' enigma: to be or not to be nucleolar. Front, Cell Dev. Biol. 12:1448209. doi: 10.3389/fcell.2024.1448209

© 2024 Khandjian, Moss, Rose, Robert and Davidovic. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these

# The fragile X proteins' enigma: to be or not to be nucleolar

Edouard W. Khandjian<sup>1\*</sup>, Tom Moss<sup>2</sup>, Timothy M. Rose<sup>3</sup>, Claude Robert<sup>4</sup> and Laetitia Davidovic<sup>5</sup>

<sup>1</sup>Département de Psychiatrie et de Neurosciences, Faculté de Médecine, Université Laval, et Centre de Recherche Cervo, Québec, QC, Canada, <sup>2</sup>Département de Biologie Moléculaire, Biochimie Médicale et Pathologie, et Centre de Recherche sur le Cancer, Axe Oncologie, Centre de Recherche du CHUQ, Université Laval, Québec, QC, Canada, <sup>3</sup>Department of Pediatrics, University of Washington, Seattle, WA, United States, <sup>4</sup>Département des Sciences Animales, Université Laval, Québec, QC, Canada, <sup>5</sup>Centre National de la Recherche Scientifique UMR7275, Institut de Pharmacologie Moléculaire et Cellulaire, Inserm U1318, Université Côte d'Azur, Valbonne, France

fragile x, nucleoli, Cajal body, translation, RNA-binding protein


#### The context

The Fragile X Messenger Ribonucleoprotein (FMRP, previously referred to as Fragile Mental Retardation Protein, see comments in Khandjian et al. (2022) is an RNA-binding protein whose mutations or absence cause Fragile X Syndrome (FXS). FMRP is mainly found in the cytoplasm and has been implicated in translation regulation. It has also been suggested to be present in the nucleolus and have a function in ribosome biogenesis. Here we wish to critically survey the data supporting this potentially important secondary function.

FMRP is the archetype of a family of cytoplasmic RNA-binding proteins that includes the Fragile X related proteins FXR1P and FXR2P. The primary transcripts of the FMR1 and FXR1, genes undergo alternative splicing processes (Ashley et al., 1993; Verkerk et al., 1993; Sittler et al., 1996; Kirkpatrick et al., 1999), resulting in multiple protein isoforms. Twelve FMRP isoforms have been detected, nine for FXR1P and one for FXR2P. Members of the Fragile X protein family are widely expressed in human tissues and in other mammals, albeit at varying levels, and expression of their isoforms is subtly choreographed (Davidovic et al., 2006a). FMRP is highly abundant in brain and testis but is absent in striated muscles. FXR1P is strongly expressed in striated muscle and testis and lower levels are detected in the brain. FXR2P expression remains almost constant in all organs and tissues. While the FMR1 gene is present on chromosome X, FXR1 and FXR2 are autosomal genes present on chromosome 12 and 17, respectively.

In humans, mutations in the FMR1 gene are the cause of FXS, a neurodevelopmental disorder that is characterized by development delay, intellectual disability, and in some cases autism spectrum disorders. FXS clinical presentation is highly heterogenous. FXS also affects peripheral tissues with patients exhibiting large everted ears, long face, increased cranial circumference, hypotonia, hyperlaxity of ligaments and macroorchidism (Hagerman et al., 2017). The most prevailing hypothesis regarding the physiopathology of FXS is that the absence of functional FMRP causes dysregulation of translation (Bassell and Warren, 2008; Darnell, 2011; Richter and Zhao, 2021). FXR1P is essential for muscle development (Mientjes et al., 2004; Huot et al., 2005) and recessive mutations in the muscle specific long isoform of FXR1P cause congenital multi-minicore myopathy in human and mice (Estañ et al., 2019), possibly by altering translation since FXR1P has been involved in translation regulation (Garnon et al., 2005; Huot et al., 2005; Vasudevan and Steitz, 2007). FXR2P is the least studied among the FXR proteins and, although it is also associated with

Khandijan et al. 10.3389/fcell.2024.1448209






FIGURE 1
Overexpression of two FMRP isoforms induce unusual structures in Cos-1 transfected cells. (A) Overexpression of full length FMRP Iso1. Shown here are three different levels of expression in transfected cells as compared to endogenous expression in two untransfected cells indicated by white arrow heads. Note the aggregates and granules detected in the cytoplasm of transfected cells. (B)
Overexpression of minor FMRP ISO6. Staining of endogenous FMRP in a non-transfected cells is shown in the left panel. Nuclear localization of exogenous FMRP ISO6 as diffuse nuclear repartition or as round shaped structures in the nucleolus (white arrows). Reproduced from (24) with permission from Biochemistry and Cellular Biology. Shown above each panel are the maps of the ISO1 full-length and the ISO6 isoform. Note the NLS, as well as the KH1 and KH2 domains in both isoforms.

the translational apparatus (Corbin et al., 1997), its role in translation regulation has not yet been formally determined.

The overall structure of the three proteins is very similar and FXR1P and FXR2P share 86% amino acid identity with FMRP in the central region, and 70% over the N-terminal region. All three proteins contain similar functional RNA-binding domains: two central KH domains (KH1 and KH2) and a C-terminal RGG domain. In addition, while the three proteins exhibit N-terminal nuclear localization signals (NLS) and a nuclear export signals (NES) between the KH and RGG domain (see maps in Figure 1) the main isoforms are exclusively detected in the cytoplasm. The C-termini of the three proteins are highly divergent and Tamanini et al. (2000) reported a nucleolar localization signal (NoLS) in FXR1P and FXR2P, which is absent in FMRP (Tamanini et al., 2000). However, some studies have challenged this view, and the issue of nucleolar localization of FMRP is the subject of the present opinion.

#### FMRP, to be or not to be nucleolar?

Shortly after the detection of endogenous FMRP associated with the translation apparatus (Khandjian et al., 1996), a follow-up study reported the sub-cellular localization of FMRP based on its overexpression after transfection with a cDNA expression vector (Willemsen et al., 1996). Using this approach, the authors detected the presence of FMRP in large cytoplasmic aggregates and even larger aggregates in the nucleolus. It is important to note that the transfection assays were performed with a vector under the control of the strong SV40 promoter, and FMRP localization was analyzed at 72 h, an astoundingly long-time post-transfection. The likelihood that the conclusions on FMRP subcellular distribution drawn in this study by Willemsen et al. (1996) are generalized to endogenous FMRP is at best questionable since overexpression most probably overloaded the cellular machinery, resulting in the artifactual localization of FMRP in both the nucleus and the nucleolus (see below).

More recently, Taha et al. (Taha et al., 2014; Taha and Ahmadian, 2024) reported that endogenous FMRP can in fact be detected in the nucleolus and suggested that cytoplasmic-nucleolar shuttling is an important aspect of FMRP function. However, it is questionable whether the immunofluorescence images presented in Figure 1B of their paper support nucleolar localization of endogenous FMRP, as the fluorescence signal is not clearly distinguishable from background, nor does it clearly colocalize with nucleolin, the nucleolar protein used as marker (even when magnified at ×500). Their choice to use the ribosomal protein RLR0 as a nucleolar marker was not judicious in the context of the nucleolus, since this acidic protein is present only in cytoplasmic ribosomes. They also found that an exogenously expressed truncated fragment of FMRP, containing the N-terminal domains, but lacking the NES, was cytoplasmic [as shown in Figure 4E of their article (Taha et al., 2014)], in clear contrast with previous reports showing nuclear localization for this type of constructs (Devys et al., 1993; Bardoni et al., 1997). Based on sequence analysis, Taha et al. claimed that FMRP possesses three previously unidentified NoLS motifs in its C-terminal domain. NoLS3: 480HGRRGPGY489, NoLS2: 526LRRGDGRRRGG536, and NoLS1: 612NQKKEKPD619, which all map to different C-terminal exons (Taha et al., 2014). While the authors conclude that these motifs in FMRP are partially conserved with the previously detected NoLS motifs in FXR1P and FXR2P (Tamanini et al., 2000) and show motifs aligned, (see Figure 4D of their article reference Taha et al. (2014), the FMRP and FXR1P/ FXR2P motifs appear unrelated since they show minimal sequence homology and are derived from distinct exonic sequences.

Importantly in the present context, a study on a FXS patient revealed a new mutation in the *FMR1* gene (Okray et al., 2015). In this patient, a Guanine (G) insertion in exon 15, at position 33020 in the gene was identified. This mutation alters the open reading frame creating a short C-terminal sequence, followed by a stop codon. This results in a mutated FMRP lacking the NES and the RGG domain similarly to the nuclear FMRP ISO6 (see below). In transfection assays using an expression vector containing the cDNA of the truncated mutant, this FMRP localizes exclusively to the nucleolus although this truncated protein does not contain the sequences of the hypothetical nucleolar localization signal (NoLS) published by Taha et al. (2014).

In support of their claims of a nucleolar localization of FMRP, Taha et al. (2014) also analyzed the presence of FMRP in subcellular

Khandjian et al. 10.3389/fcell.2024.1448209

organelles including nucleoli and in immunoprecipitates and reported that FMRP was as abundant in the nucleolus as in the cytosolic fractions. However, the experimental procedure used to obtain these organelles is highly questionable as it involved nuclear disruption by gentle homogenization with a Balch homogenizer. Well-established cellular fractionation procedures all agree that nucleoli extraction requires nuclei disruption by sonification to share the viscous chromatin and free the organelles (see seminal work, for instance from Harris Busch, Jean-Pierre Zalta, in the 60's). Also, there is no universal method to purify all cell components based on a single cell lysis technique such as the one used by Taha et al. (2014). They also claimed that FMRP is associated with mitochondria without controlling for the possible contamination with the rough endoplasmic reticulum that contains polyribosomes and by consequence FMRP. Based on these technical considerations, we believe there are serious concerns regarding the conclusions drawn by Taha et al. (Taha et al., 2014; Taha and Ahmadian, 2024), which more than likely stem from over enthusiastic interpretation of the images and the use of inadequate experimental procedures. Finally, they concluded their study by transfection assays using a pcDNA3 eukaryotic expression vector in which FMR1 full-length cDNA as well several truncated forms were expressed under the strong cytomegalovirus (CMV) promoter. The atypically shape of the nucleoli stained with anti-nucleolin antibodies (their Figure 4 in Taha et al. (2014), suggests that the transfected cells were likely undergoing distress, once again questioning the conclusions drawn.

# Avoiding traps to solve the problem in future studies

Although the expression of exogenous proteins via transfection assays is a convenient approach to study subcellular localization, we posit that results obtained may not necessarily be generalizable to the native endogenous protein that is subjected to natural regulation of its expression level that is tightly linked to the cellular state (e.g., mitotic, quiescent, metabolic, stressed ...). Based on our long-standing experience, overexpressing of FMRP at high levels and for extended periods of time results in unusual if not atypical images. Our longstanding experience related to the use of exogenous FMRP support this. In the late 1990's, we transfected Cos-3 cells (Khandjian, 1999) independently with two FMR1 cDNA variants under the control of the simian virus (SV40) promotor in the pTL1 vector to allow expression of the longest FMRP isoform (ISO1, 632 aa) and a minor isoform (ISO6, 537 aa) in which a frame shift at aa 425 in the C-terminus causes a premature truncation of the protein and the absence of the NES and RGG domains (Dury et al., 2013). After 24 h of transfection, cells were fixed and stained with the mAb1C3 monoclonal antibody that recognizes the constitutive N-terminal part (aa 66-112) of FMRP present in all isoforms. In untransfected cells (white arrow heads in Figure 1A), FMRP exhibited its classical, cytoplasmic staining while nuclear staining was absent. In contrast, cells overexpressing ISO1 exhibit strong reactive aggregates and granules in the cytoplasm. Subsequently, we have shown that these granules correspond to stress granules that sequester mRNA and many other RNA-binding proteins (Mazroui et al., 2002). These stress granules form in response to cellular stress (heat shock, hypoxia, arsenite, UVC, etc.) and maintain translational repression until the stress is relieved.

Regarding FMRP ISO6, half of the transfected cells exhibited a strong ring-shape staining surrounding the nucleolus, while the other half exhibited a punctuate staining in the nucleus (Khandjian, 1999). However, in the latter case, the nucleoli appeared irregular in shape (Figure 1B). Being truncated, FMRP ISO6 isoform only contains the N-terminal and C-central regions and lacks the three putative C-terminal NoLS motifs described by Taha et al. (2014) that, in contrast to the early data, were found by these authors to be distributed uniformly throughout nucleus and cytoplasm (their Figure 1b in Taha et al. (2014)). Furthermore, the ring-shaped nucleolar structures which we observed and are absent under normal growth conditions, are reminiscent of the nucleolar detention centers (DC) in which proteins are temporarily detained in response to cellular stresses (Audas et al., 2012a; Audas et al., 2012b; Jacob et al., 2013). Such structural remodeling leaves nucleoli temporarily unable to sustain their primary function of ribosomal biogenesis until stress is relieved. In a certain way, formation of DC could be the nucleolar counterpart of cytoplasmic stress granules formation (see above).

Bearing all this in mind, we have paid attention in our work to limiting FMRP transient expression of FMRP to less than 18 h, in contrast to many studies in the field that used up to 72 h. In this context, the minor FMRP ISO6 clearly localizes to nucleoli (Davidovic et al., 2006b) and Cajal Bodies (Dury et al., 2013). These two organelles have been previously described notably a century ago (Garcia-Lopez et al., 2010) to be in direct physical contact. Much more recently, it was observed in HeLa cells that Cajal Bodies shuttle in and out of nucleoli (Gall, 2000; Platani et al., 2000; Cioce and Lamond, 2005). Our results are in line with this model.

Taking these considerations together, we suggest that there is a lack of convincing literature-based evidence to support a nucleolar role for full-length FMRP ISO1 in ribosome biogenesis. Rather we suggest that the artificial transient overexpression conditions used in most studies, disturbs cellular homeostasis and leads to FMRP mis-localization. We hope that this opinion will serve as a reference for future studies exploring the nuclear and more specifically nucleolar roles of FMRP.

#### **Author contributions**

EK: Conceptualization, Writing-original draft. TM: Writing-review and editing. TR: Formal Analysis, Writing-review and editing. CR: Writing-review and editing. LD: Writing-review and editing.

### **Funding**

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

#### Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Khandjian et al. 10.3389/fcell.2024.1448209

#### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

#### References

Ashley, C. T., Sutcliffe, J. S., Kunst, C. B., Leiner, H. A., Eichler, E. E., Nelson, D. L., et al. (1993). Human and murine FMR-1: alternative splicing and translational initiation downstream of the CGG-repeat. *Nat. Genet.* 4, 244–251. doi:10.1038/ng0793-244

Audas, T. E., Jacob, M. D., and Lee, S. (2012a). The nucleolar detention pathway: a cellular strategy for regulating molecular networks. *Cell Cycle* 11, 2059–2062. doi:10.

Audas, T. E., Jacob, M. D., and Lee, S. (2012b). Immobilization of proteins in the nucleolus by ribosomal intergenic spacer noncoding RNA. *Mol. Cell* 45, 147–157. doi:10.1016/j.molcel.2011.12.012

Bardoni, B., Sittler, A., Shen, Y., and Mandel, J. L. (1997). Analysis of domains affecting intracellular localization of the FMRP protein. *Neurobiol Dis.* 4, 329–336. doi:10.1006/nbdi.1997.0142

Bassell, G. J., and Warren, S. T. (2008). Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. *Neuron* 60, 201–214. doi:10.1016/j.neuron.2008.10.004

Cioce, M., and Lamond, A. I. (2005). Cajal bodies: a long history of discovery. Annu. Rev. Cell Dev. Biol. 21, 105–131. doi:10.1146/annurev.cellbio.20.010403.103738

Corbin, F., Bouillon, M., Anny Fortin, A., Morin, S., Rousseau, F., and Khandjian, E. W. (1997). The fragile X mental retardation protein is associated with poly(A) $^+$  mRNA in actively translating polyribosomes. *Hum. Mol. Genet.* 6, 1465–1472. doi:10.1093/hmg/6.9.1465

Darnell, J. C. (2011). Defects in translational regulation contributing to human cognitive and behavioral disease. *Cur Opin. Genet. Dev.* 21, 465–473. doi:10.1016/j.gde. 2011.05.002

Davidovic, L., Bechara, E., Gravel, M., Jaglin, X. H., Tremblay, S., Sik, A., et al. (2006b). The nuclear microspherule protein 58 is a novel RNA-binding protein that interacts with fragile X mental retardation protein in polyribosomal mRNPs from neurons. *Hum. Mol. Genet.* 15, 1525–1538. doi:10.1093/hmg/ddl074

Davidovic, L., Tremblay, S., Gravel, M., De Koninck, P., and Khandjian, E. W. (2006a). The fragile X syndrome: one protein missing and 1001 disoriented mRNAs. *Med. Sci. Paris.* 22 (1), 41–46. doi:10.1051/medsci/200622141

Devys, D., Lutz, Y., Rouyer, N., Belloq, J. P., and Mandel, J. L. (1993). The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. *Nat. Genet.* 4, 335–340. doi:10.1038/ng0893-335

Dury, A. Y., El Fatimy, R., Tremblay, S., Rose, T. M., Côté, J., De Koninck, P., et al. (2013). Nuclear fragile X mental retardation protein is localized to cajal bodies. *PLoS Genet.* 9 (10), e1003890. doi:10.1371/journal.pgen.1003890

Estañ, M. C., Fernández-Núñez, E., Zaki, M. S., Esteban, M. I., Donkervoon, S., Hawkins, C., et al. (2019). Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. *Nat. Comm.* 10, 797. doi:10.1038/s41467-019-08548-9

Gall, J. G. (2000). Cajal bodies: the first 100 years. *Annu. Rev. Cell Dev. Biol.* 16, 273–300. doi:10.1146/annurev.cellbio.16.1.273

Garcia-Lopez, P., Garcia-Marin, V., and Freire, M. (2010). The histological slides and drawings of Cajal. *Front. Neuroanat.* 4, 9–16. doi:10.3389/neuro.05.009.2010

Garnon, J., Lachance, C., Di Marco, S., Hel, Z., Marion, D., Ruiz, M. C., et al. (2005). Fragile X-related protein FXR1P regulates proinflammatory cytokine tumor necrosis factor expression at the post-transcriptional level. *J. Biol. Chem.* 280, 5750–5763. doi:10. 1074/jbc.M401988200

Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Jr, Moine, H., Kooy, R. F., et al. (2017). Fragile X syndrome. *Nat. Rev. Dis. Prim.* 29 (3), 17065. doi:10.1038/nrdp.2017.65

Huot, M.-E., Bisson, N., Davidovic, L., Mazroui, R., Labelle, Y., Moss, T., et al. (2005). The RNA-binding protein fragile X-related 1 regulates somite formation in *Xenopus laevis*. *Mol. Biol. Cell* 16, 4350–4361. doi:10.1091/mbc.e05-04-0304

Jacob, M. D., Audas, T. E., Uniacke, J., Trinkle-Mulcahy, L., and Lee, S. (2013). Environmental cues induce a long noncoding RNA-dependent remodeling of the nucleolus. *Mol. Biol. Cell* 24, 2943–2953. doi:10.1091/mbc.E13-04-0223

Khandjian, E. W. (1999). Biology of the fragile X mental retardation protein, an RNA-binding protein. *Biochem. Cell Biol.* 77, 331–342. doi:10.1139/bcb-77-4-331

Khandjian, E. W., Corbin, F., Woerly, S., and Rousseau, F. (1996). The fragile X mental retardation protein is associated with ribosomes. *Nat. Genet.* 12, 91–93. doi:10. 1038/ng0196-91

Khandjian, E. W., Robert, C., and Davidovic, L. (2022). FMRP, a multifunctional RNA-binding protein in quest of a new identity. *Front. Genet.* 13, 976480. doi:10.3389/fgene.2022.976480

Kirkpatrick, L. L., McIlwain, K. A., and Nelson, D. L. (1999). Alternative splicing in the murine and human FXR1 genes. *Genomics* 59, 193–202. doi:10.1006/geno.1999.

Mazroui, R., Huot, M. E., Tremblay, S., Filion, C., Labelle, Y., and Khandjian, E. W. (2002). Trapping of messenger RNA by Fragile X Mental Retardation protein into cytoplasmic granules induces translation repression. *Hum. Mol. Genet.* 11, 3007–3017. doi:10.1093/hmg/11.24.3007

Mientjes, E. J., Willemsen, R., Kirkpatrick, L. L., Nieuwenhuizen, I. M., Hoogeveen-Westerveld, M., Verweij, M., et al. (2004). Fxr1 knockout mice show a striated muscle phenotype: implications for Fxr1p function *in vivo. Hum. Mol. Genet.* 13, 1291–1302. doi:10.1093/hmg/ddh150

Okray, Z., de Esch, C. E. F., Van Esch, H., Devriendt, K., Claeys, A., Yan, J., et al. (2015). A novel fragile X syndrome mutation reveals a conserved role for the carboxy-terminus in FMRP localization and function. *EMBO Mol. Med.* 7, 423–437. doi:10.15252/emmm.201404576

Platani, M., Goldberg, I., Swedlow, J. R., and Lamond, A. I. (2000). *In vivo* analysis of Cajal body movement, separation, and joining in live human cells. *J. Cell Biol.* 151, 1561–1574. doi:10.1083/jcb.151.7.1561

Richter, J. D., and Zhao, X. (2021). The molecular biology of FMRP: new insights into fragile X syndrome. *Nat. Rev. Neurosci.* 22, 209–222. doi:10.1038/s41583-021-00432-0

Sittler, A., Devys, D., Weber, C., and Mandel, J.-L. (1996). Alternative splicing of exon 14 determines nuclear or cytoplasmic localisation of fmr1 protein isoforms. *Hum. Mol. Genet.* 5, 95–102. doi:10.1093/hmg/5.1.95

Taha, M. S., and Ahmadian, M. R. (2024). Fragile X messenger Ribonucleoprotein protein and its multifunctionality: from cytosol to nucleolus and back. *Biomolecules* 14 (4), 399. doi:10.3390/biom14040399

Taha, M. S., Nouri, K., Milroy, L. G., Moll, J. M., Herrmann, C., Brunsveld, L., et al. (2014). Subcellular fractionation and localization studies reveal a direct interaction of the fragile X mental retardation protein (FMRP) with nucleolin. *PLoS One* 9 (3), e91465. doi:10.1371/journal.pone.0091465

Tamanini, F., Kirkpatric, L. L., Schonkeren, J., van Unen, L., Bontekoe, C., Bakker, C., et al. (2000). The fragile X-related proteins FXR1P and FXR2P contain a functional nucleolar-targeting signal equivalent to the HIV-1 regulatory proteins. *Hum. Mol. Genet.* 9, 1487–1493. doi:10.1093/hmg/9.10.1487

Vasudevan, S., and Steitz, J. A. (2007). AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. *Cell* 128, 1105–1118. doi:10.1016/j.cell.2007.

Verkerk, AJMH, de Graaf, E., De Boulle, K., Eichler, E. E., Koonecki, D. S., Reyniers, E., et al. (1993). Alternative splicing in the fragile X gene FMR1. *Hum. Mol. Genet.* 2, 399–404. doi:10.1093/hmg/2.4.399

Willemsen, R., Bontekoe, C., Tamanini, F., Galjaard, H., Hoogeveen, A., and Oostra, B. (1996). Association of FMRP with ribosomal precursor particles in the nucleolus. *Biochem. Biophys. Res. Comm.* 225, 27–33. doi:10.1006/bbrc.1996.1126